10-Q quarterly report · filed Nov 3, 2026

RHYTHM PHARMACEUTICALS, INC. (RYTM) Q3 2026 10-Q Quarterly Report

Short answer

RHYTHM PHARMACEUTICALS, INC. (RYTM) filed its Q3 2026 10-Q quarterly report on Nov 3, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $92M (up 79.6% year over year) with net income of −$41M.

Q3 2026 key financials · XBRL

Revenue
$92M
+79.6% YoY · +29.3% QoQ
Net income
−$41M
+21.8% YoY · +16.1% QoQ
Operating margin
-42.6%
EPS (diluted)
−$0.61
+25.6% YoY · +17.6% QoQ

Source: XBRL data from the RHYTHM PHARMACEUTICALS, INC. (RYTM) Q3 2026 10-Q on SEC EDGAR. USD.

RHYTHM PHARMACEUTICALS, INC. Q3 2026 10-Q analysis

AI summary of MD&A and risk factor updates

Management Discussion & Analysis

  • Q3 revenue $92.1M, up 80% YoY from $51.3M, driven by higher domestic and international IMCIVREE volume
  • Net loss $41.4M vs $52.9M; operating loss $39.3M vs $52.7M
  • U.S. IMCIVREE revenue $67.5M, 73% of product revenue; ex-U.S. revenue $24.7M
  • Cash, equivalents and short-term investments $320.9M; operating cash use $56.4M for nine months vs $90.3M
  • Outlook: bivamelagon Phase 3 initiation by year-end 2026; $350.0M LGC obligation and term-loan access up to $750.0M increasing fixed obligations

Risk Factors

  • Newly added financing risk: November 2, 2026 A&R RIFA and up to $750.0 million term loan introduced additional repayment and covenant obligations
  • Most materially updated financial risk: RIFA amendment and term loan could restrict financing, acquisitions, asset sales and other operations
  • Regulatory risk: EU IVDR class C companion diagnostics transition deadline reached May 26, 2026
  • Operational risk: reliance on specialty pharmacy for significant U.S. revenue makes distributor transitions capable of reducing revenue and cash flows
  • Financial risk: $320.9 million cash and investments, with uninsured deposits exposed to financial-institution failure

Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K

Other RHYTHM PHARMACEUTICALS, INC. quarterly reports

Ask about this quarter

Compare quarters, check guidance or see what insiders and funds did around the report.